PDF(Pubmed)
Abstract：
BACKGROUND: Heart failure (HF) is a significant health problem that is often associated with major morbidity and mortality. Metabolic abnormalities occur in HF and may be used to identify individuals at risk of developing the condition. Furthermore, these metabolic changes may play a role in the pathogenesis and progression of HF. Despite this knowledge, the utility of metabolic changes in diagnosis, management, prognosis, and therapy for patients with chronic HF has not been systematically reviewed.
OBJECTIVE: This scoping review aims to systematically appraise the literature on metabolic changes in patients with HF, describe the role of these changes in pathogenesis, progression, and care, and identify knowledge gaps to inform future research.
METHODS: This review will be conducted using a strategy based on previous reports, the JBI Manual for Evidence Synthesis, and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR) guidelines. A comprehensive search of electronic databases (Medline, EBSCOhost, Scopus, and Web of Science) will be conducted using keywords related to HF, myocardial failure, metabolomes, metabonomics, and analytical chemistry techniques. The search will include original peer-reviewed research papers (clinical studies conducted on humans and systematic reviews with or without a meta-analysis) published between January 2010 and September 2023. Studies that include patients with HF younger than 18 years or those not published in English will be excluded. Two authors (UGA and MB) will screen the titles and abstracts independently and perform a full-text screen of the relevant and eligible papers. Relevant data will be extracted and synthesized, and a third author or group will be consulted to resolve discrepancies.
RESULTS: This scoping review will span from January 2010 to September 2023, and the results will be published in a peer-reviewed, open-access journal as a scoping review in 2024. The presentation of the findings will use the PRISMA-ScR flow diagram and descriptive and narrative formats, including tables and graphical displays, to provide a comprehensive overview of the extracted data.
CONCLUSIONS: This review aims to collect and analyze the available evidence on metabolic changes in patients with HF, aiming to enhance our current understanding of this topic. Additionally, this review will identify the most commonly used and suitable sample, analytical method, and specific metabolomes to facilitate standardization, reproducibility of results, and application in the diagnosis, treatment, and risk stratification of patients with HF. Finally, it is hoped that this review\'s outcomes will inspire further research into the metabolomes of patients with HF in low- and middle-income countries.
BACKGROUND: Open Science Framework; https://osf.io/sp6xj.
UNASSIGNED: DERR1-10.2196/53905.
OBJECTIVE: This scoping review aims to systematically appraise the literature on metabolic changes in patients with HF, describe the role of these changes in pathogenesis, progression, and care, and identify knowledge gaps to inform future research.
METHODS: This review will be conducted using a strategy based on previous reports, the JBI Manual for Evidence Synthesis, and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR) guidelines. A comprehensive search of electronic databases (Medline, EBSCOhost, Scopus, and Web of Science) will be conducted using keywords related to HF, myocardial failure, metabolomes, metabonomics, and analytical chemistry techniques. The search will include original peer-reviewed research papers (clinical studies conducted on humans and systematic reviews with or without a meta-analysis) published between January 2010 and September 2023. Studies that include patients with HF younger than 18 years or those not published in English will be excluded. Two authors (UGA and MB) will screen the titles and abstracts independently and perform a full-text screen of the relevant and eligible papers. Relevant data will be extracted and synthesized, and a third author or group will be consulted to resolve discrepancies.
RESULTS: This scoping review will span from January 2010 to September 2023, and the results will be published in a peer-reviewed, open-access journal as a scoping review in 2024. The presentation of the findings will use the PRISMA-ScR flow diagram and descriptive and narrative formats, including tables and graphical displays, to provide a comprehensive overview of the extracted data.
CONCLUSIONS: This review aims to collect and analyze the available evidence on metabolic changes in patients with HF, aiming to enhance our current understanding of this topic. Additionally, this review will identify the most commonly used and suitable sample, analytical method, and specific metabolomes to facilitate standardization, reproducibility of results, and application in the diagnosis, treatment, and risk stratification of patients with HF. Finally, it is hoped that this review\'s outcomes will inspire further research into the metabolomes of patients with HF in low- and middle-income countries.
BACKGROUND: Open Science Framework; https://osf.io/sp6xj.
UNASSIGNED: DERR1-10.2196/53905.
摘要：
背景：心力衰竭（HF）是一种重要的健康问题，通常与主要的发病率和死亡率有关。代谢异常发生在HF中，可用于识别有发展该疾病风险的个体。此外，这些代谢变化可能在HF的发病和进展中起作用。尽管有这些知识,代谢变化在诊断中的效用，管理,预后,慢性HF患者的治疗尚未进行系统评价。
目的：本范围综述旨在系统评价HF患者代谢变化的文献，描述这些变化在发病机理中的作用，programming,和关心，并确定知识差距，为未来的研究提供信息。
方法：本审查将使用基于以前报告的策略进行，JBI证据综合手册，以及系统审查的首选报告项目和范围审查的荟萃分析扩展（PRISMA-ScR）指南。对电子数据库的全面搜索(Medline，EBSCOhost,Scopus,和WebofScience)将使用与HF相关的关键字进行，心肌衰竭,代谢组，代谢组学，和分析化学技术。搜索将包括2010年1月至2023年9月之间发表的原始同行评审的研究论文（对人类进行的临床研究以及带有或不带有荟萃分析的系统综述）。包括18岁以下或未发表英语的HF患者的研究将被排除。两位作者（UGA和MB）将独立筛选标题和摘要，并对相关和符合条件的论文进行全文筛选。相关数据将被提取和合成，并将咨询第三作者或小组以解决差异。
结果：这项范围界定审查将从2010年1月到2023年9月，其结果将以同行评审的方式发布，开放获取期刊作为2024年的范围审查。调查结果的介绍将使用PRISMA-ScR流程图以及描述性和描述性格式，包括表格和图形显示，提供提取数据的全面概述。
结论：本综述旨在收集和分析HF患者代谢变化的现有证据，旨在增强我们当前对这个主题的理解。此外,这篇综述将确定最常用和最合适的样本，分析方法，和特定的代谢组来促进标准化，结果的再现性，以及在诊断中的应用，治疗,和HF患者的危险分层。最后,希望这篇综述的结果将激发对低收入和中等收入国家HF患者代谢组的进一步研究.
背景：开放科学框架；https://osf.io/sp6xj。
■DERR1-10.2196/53905。
目的：本范围综述旨在系统评价HF患者代谢变化的文献，描述这些变化在发病机理中的作用，programming,和关心，并确定知识差距，为未来的研究提供信息。
方法：本审查将使用基于以前报告的策略进行，JBI证据综合手册，以及系统审查的首选报告项目和范围审查的荟萃分析扩展（PRISMA-ScR）指南。对电子数据库的全面搜索(Medline，EBSCOhost,Scopus,和WebofScience)将使用与HF相关的关键字进行，心肌衰竭,代谢组，代谢组学，和分析化学技术。搜索将包括2010年1月至2023年9月之间发表的原始同行评审的研究论文（对人类进行的临床研究以及带有或不带有荟萃分析的系统综述）。包括18岁以下或未发表英语的HF患者的研究将被排除。两位作者（UGA和MB）将独立筛选标题和摘要，并对相关和符合条件的论文进行全文筛选。相关数据将被提取和合成，并将咨询第三作者或小组以解决差异。
结果：这项范围界定审查将从2010年1月到2023年9月，其结果将以同行评审的方式发布，开放获取期刊作为2024年的范围审查。调查结果的介绍将使用PRISMA-ScR流程图以及描述性和描述性格式，包括表格和图形显示，提供提取数据的全面概述。
结论：本综述旨在收集和分析HF患者代谢变化的现有证据，旨在增强我们当前对这个主题的理解。此外,这篇综述将确定最常用和最合适的样本，分析方法，和特定的代谢组来促进标准化，结果的再现性，以及在诊断中的应用，治疗,和HF患者的危险分层。最后,希望这篇综述的结果将激发对低收入和中等收入国家HF患者代谢组的进一步研究.
背景：开放科学框架；https://osf.io/sp6xj。
■DERR1-10.2196/53905。
